Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) have been given an average rating of "Buy" by the eight research firms that are presently covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $32.83.
Separately, Cantor Fitzgerald upgraded shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, June 5th.
Read Our Latest Stock Analysis on Catalyst Pharmaceuticals
Catalyst Pharmaceuticals Stock Down 2.0%
Shares of CPRX stock opened at $21.03 on Friday. The firm's 50 day moving average price is $23.23 and its two-hundred day moving average price is $22.89. Catalyst Pharmaceuticals has a fifty-two week low of $15.34 and a fifty-two week high of $26.58. The stock has a market cap of $2.57 billion, a price-to-earnings ratio of 13.39, a price-to-earnings-growth ratio of 0.86 and a beta of 0.66.
Insider Buying and Selling
In other news, insider Gary Ingenito sold 200,000 shares of Catalyst Pharmaceuticals stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $23.68, for a total value of $4,736,000.00. Following the completion of the transaction, the insider directly owned 68,873 shares in the company, valued at approximately $1,630,912.64. The trade was a 74.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Preethi Sundaram sold 2,324 shares of the stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $26.41, for a total value of $61,376.84. Following the completion of the transaction, the insider directly owned 42,681 shares in the company, valued at approximately $1,127,205.21. This represents a 5.16% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 247,924 shares of company stock worth $5,879,369 in the last 90 days. Company insiders own 10.40% of the company's stock.
Institutional Trading of Catalyst Pharmaceuticals
A number of institutional investors and hedge funds have recently bought and sold shares of the company. Algert Global LLC raised its stake in Catalyst Pharmaceuticals by 1.0% during the 1st quarter. Algert Global LLC now owns 48,390 shares of the biopharmaceutical company's stock valued at $1,173,000 after purchasing an additional 470 shares during the period. Hancock Whitney Corp boosted its position in shares of Catalyst Pharmaceuticals by 1.4% during the first quarter. Hancock Whitney Corp now owns 38,847 shares of the biopharmaceutical company's stock valued at $942,000 after buying an additional 525 shares during the period. GAMMA Investing LLC grew its position in Catalyst Pharmaceuticals by 26.2% in the 1st quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock valued at $68,000 after acquiring an additional 579 shares during the last quarter. Summit Investment Advisors Inc. lifted its holdings in Catalyst Pharmaceuticals by 5.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 11,696 shares of the biopharmaceutical company's stock valued at $244,000 after buying an additional 580 shares in the last quarter. Finally, Hohimer Wealth Management LLC grew its position in shares of Catalyst Pharmaceuticals by 3.6% during the 1st quarter. Hohimer Wealth Management LLC now owns 18,070 shares of the biopharmaceutical company's stock worth $438,000 after buying an additional 629 shares in the last quarter. 79.22% of the stock is currently owned by institutional investors.
About Catalyst Pharmaceuticals
(
Get Free ReportCatalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Catalyst Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Catalyst Pharmaceuticals wasn't on the list.
While Catalyst Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
